Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code. Renewal of inclusion on the list of medicines refundable by National Health Insurance.
-
Clinical Benefit
Substantial
The actual benefit of LEPONEX in the treatment of schizophrenia remains substantial.
The actual benefit of LEPONEX in this indication remains substantial.
Clinical Added Value
moderate
As a second-line therapy, LEPONEX provides a moderate improvement in actual benefit (IAB III) as regards its indication for the treatment of schizophrenia.
Listen
